Cargando…

The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies

OBJECTIVES: BioNTech (Pfizer) and CoronaVac (Sinovac) vaccines are two of the most administered coronavirus disease-2019 (COVID-19) vaccines worldwide. Vaccination against severe acute respiratory syndrome-coronavirus-2 has caused a diagnostic challenge in oncological (18)F-fluorodeoxyglucose (FDG)...

Descripción completa

Detalles Bibliográficos
Autores principales: Şan, Hüseyin, Alagöz, Engin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586001/
https://www.ncbi.nlm.nih.gov/pubmed/36268854
http://dx.doi.org/10.4274/mirt.galenos.2022.86570
_version_ 1784813612517294080
author Şan, Hüseyin
Alagöz, Engin
author_facet Şan, Hüseyin
Alagöz, Engin
author_sort Şan, Hüseyin
collection PubMed
description OBJECTIVES: BioNTech (Pfizer) and CoronaVac (Sinovac) vaccines are two of the most administered coronavirus disease-2019 (COVID-19) vaccines worldwide. Vaccination against severe acute respiratory syndrome-coronavirus-2 has caused a diagnostic challenge in oncological (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) studies. The aim of our study was to evaluate the (18)F-FDG PET/CT findings of the two most commonly administered vaccines worldwide. METHODS: Patients over 18 years old who underwent (18)F-FDG PET/CT for oncological purposes in our institution between January 13, 2021 and January 31, 2022, who received a single or second dose of the BioNTech or CoronaVac vaccines in the last two months, were included in the study. Descriptive analyses were presented as mean, standard deviation, frequency and ratio. Additionally, chi-square test was used to analyze categorical variables. RESULTS: Ipsilateral deltoid muscle hypermetabolism was observed in 6.9% (n=15) and 14.3% (n=22) patients who received CoronaVac and BioNTech vaccines, respectively. Ipsilateral axillary lymph node hypermetabolism was observed in 11% (n=24) and 41.6% (n=64) patients who received CoronaVac and BioNTech vaccines, respectively. Synchronous deltoid muscle and axillary lymph node hypermetabolism was observed in 4.14% (n=9) and 12.33% (n=19) patients who received CoronaVac and BioNTech vaccines, respectively. Significant differences were detected between CoronaVac and BioNTech vaccines in terms of ipsilateral deltoid muscle hypermetabolism, ipsilateral axillary lymph node hypermetabolism and synchronous deltoid muscle and axillary lymph node hypermetabolism (p<0.05). CONCLUSION: COVID-19 vaccination may result in ipsilateral axillary lymph node hypermetabolism, ipsilateral deltoid muscle hypermetabolism, or synchronous deltoid muscle and axillary lymph node hypermetabolism with different frequencies depending on the type of vaccination. Although synchronous deltoid muscle and axillary lymph node hypermetabolism can reduce misinterpretation of (18)F-FDG PET/CT, to avoid misinterpretation, it is important to question the vaccination history during ongoing COVID-19 vaccination process.
format Online
Article
Text
id pubmed-9586001
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-95860012022-10-26 The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies Şan, Hüseyin Alagöz, Engin Mol Imaging Radionucl Ther Original Article OBJECTIVES: BioNTech (Pfizer) and CoronaVac (Sinovac) vaccines are two of the most administered coronavirus disease-2019 (COVID-19) vaccines worldwide. Vaccination against severe acute respiratory syndrome-coronavirus-2 has caused a diagnostic challenge in oncological (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) studies. The aim of our study was to evaluate the (18)F-FDG PET/CT findings of the two most commonly administered vaccines worldwide. METHODS: Patients over 18 years old who underwent (18)F-FDG PET/CT for oncological purposes in our institution between January 13, 2021 and January 31, 2022, who received a single or second dose of the BioNTech or CoronaVac vaccines in the last two months, were included in the study. Descriptive analyses were presented as mean, standard deviation, frequency and ratio. Additionally, chi-square test was used to analyze categorical variables. RESULTS: Ipsilateral deltoid muscle hypermetabolism was observed in 6.9% (n=15) and 14.3% (n=22) patients who received CoronaVac and BioNTech vaccines, respectively. Ipsilateral axillary lymph node hypermetabolism was observed in 11% (n=24) and 41.6% (n=64) patients who received CoronaVac and BioNTech vaccines, respectively. Synchronous deltoid muscle and axillary lymph node hypermetabolism was observed in 4.14% (n=9) and 12.33% (n=19) patients who received CoronaVac and BioNTech vaccines, respectively. Significant differences were detected between CoronaVac and BioNTech vaccines in terms of ipsilateral deltoid muscle hypermetabolism, ipsilateral axillary lymph node hypermetabolism and synchronous deltoid muscle and axillary lymph node hypermetabolism (p<0.05). CONCLUSION: COVID-19 vaccination may result in ipsilateral axillary lymph node hypermetabolism, ipsilateral deltoid muscle hypermetabolism, or synchronous deltoid muscle and axillary lymph node hypermetabolism with different frequencies depending on the type of vaccination. Although synchronous deltoid muscle and axillary lymph node hypermetabolism can reduce misinterpretation of (18)F-FDG PET/CT, to avoid misinterpretation, it is important to question the vaccination history during ongoing COVID-19 vaccination process. Galenos Publishing 2022-10 2022-10-19 /pmc/articles/PMC9586001/ /pubmed/36268854 http://dx.doi.org/10.4274/mirt.galenos.2022.86570 Text en ©Copyright 2022 by Turkish Society of Nuclear Medicine | Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Şan, Hüseyin
Alagöz, Engin
The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
title The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
title_full The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
title_fullStr The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
title_full_unstemmed The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
title_short The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
title_sort effects of coronavac (sinovac) and bnt162b2 (biontech/pfizer) vaccination on oncologic (18)f-fdg pet/ct studies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586001/
https://www.ncbi.nlm.nih.gov/pubmed/36268854
http://dx.doi.org/10.4274/mirt.galenos.2022.86570
work_keys_str_mv AT sanhuseyin theeffectsofcoronavacsinovacandbnt162b2biontechpfizervaccinationononcologic18ffdgpetctstudies
AT alagozengin theeffectsofcoronavacsinovacandbnt162b2biontechpfizervaccinationononcologic18ffdgpetctstudies
AT sanhuseyin effectsofcoronavacsinovacandbnt162b2biontechpfizervaccinationononcologic18ffdgpetctstudies
AT alagozengin effectsofcoronavacsinovacandbnt162b2biontechpfizervaccinationononcologic18ffdgpetctstudies